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The 2009 Annual Meeting of the 
International Pachyonychia Congenita 
Consortium (IPCC)* centered on the 
need to develop patient-friendly tech-
nologies to effectively and efficiently 
deliver nucleic acids to skin. The IPCC 
is a group of physicians and scientists 
who have agreed to work together to 
develop therapeutics for the rare skin 
disorder pachyonychia congenita (PC) 
(a list of IPCC members can be found 
at http://www.pachyonychia.org). Each 
year’s IPCC meeting is devoted to the 
most pressing issues related to devel-
oping PC therapeutics and to identify-
ing future directions toward achieving 
realistic goals. The consortium fully 
recognizes and expects that research 
success in this realm will be of imme-
diate benefit not only to patients with 
PC but also to those suffering from 
other skin disorders.
The 2009 meeting addressed the dif-
ficulty of delivering nucleic acids to 
skin. The impetus for this topic was the 
recent phase Ib pachyonychia congenita 
clinical trial using a mutation-specific 
small interfering RNA (siRNA), TD101. 
The side-by-side, dose-escalation 
toxicity trial of intralesional injections 
of this mutation-specific siRNA exhib-
ited no toxicity at the higher doses, 
and a clear clinical response was 
observed in the siRNA-treated site, but 
not in the site injected with vehicle 
alone (Leachman et al., submitted). 
Unfortunately, pain from the injec-
tions was intolerable, and a decision 
was made that better delivery options 
were needed before further trials were 
pursued.
The meeting was divided into four 
areas: (i) a historical overview high-
lighting the need for nucleic acid 
skin delivery, (ii) delivery technolo-
gies used in recent clinical trials, (iii) 
delivery technologies currently under 
development, and (iv) future direc-
tions in the development of nucleic 
acid skin delivery technologies that 
will be acceptable and effective.
the need to deliver  
nucleic acid therapies to skin
Nicholas Dean explained the urgent 
need for better ways to deliver nucle-
ic acids. He pointed out that steady 
progress has been made in the devel-
opment of oligonucleotide-based 
drugs over the past 20 years and that 
the pharmacokinetics, toxicology, 
and pharmacology of many classes 
of single- and double-stranded oli-
gonucleotides are understood in 
detail. Furthermore, many of the chal-
lenges to development and commer-
cialization of these drugs are being 
overcome, with more than 30 oligo-
nucleotide drugs now progressing 
in non-skin clinical trials. However, 
important technological hurdles must 
be overcome before the therapeutic 
potential of oligonucleotides in skin 
can be realized.
Joseph Carroll (formerly of Sirna 
Pharmaceuticals) shared his experi-
ence in developing topical formula-
tions while directing the skin siRNA 
program at Sirna. The short time need-
ed to identify and manufacture potent 
and specific siRNAs is attractive to 
the pharmaceutical industry, and the 
cost of production is now decreasing. 
This project was discontinued after 
Merck acquired Sirna, but several 
formulations were optimized at Sirna 
to allow efficient delivery of labeled 
siRNA through the stratum corneum, 
although they were not functionally 
active. A point of discussion through-
out the meeting was that delivery of 
siRNA through the stratum corneum is 
necessary but not sufficient for deliv-
ery to epidermal cells and that addi-
tional steps must be taken to facilitate 
nucleic acid uptake by keratinocytes 
(and endosomal release) to allow 
access to the RNA-induced silencing 
complex (i.e., no “magic bullet cur-
rently exists for both barrier disrup-
tion and intracellular delivery”). Dr 
Carroll noted the complexities in for-
mulating siRNA, including the need 
for compatibility of excipients with 
siRNA, development of penetration 
enhancers, avoiding inflammation 
(which causes epidermal thicken-
ing, reducing siRNA penetration), 
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limiting off-target effects, and testing 
of formulations on preclinical models 
(with subsequent re-optimization in 
humans).
Success in clinical trials
Several presenters described suc-
cessful clinical trials using nucleic 
acids delivered to the skin. Sancy 
Leachman reported the first clinical 
trial of an siRNA (TD101) delivered to 
skin (it is also the first siRNA to target 
a mutant mRNA). Although signs of 
efficacy were clearly apparent, with 
the treated skin reverting to “normal” 
(non-tender) skin at the site of siRNA 
injection, pain associated with intra-
lesional injections required regional 
nerve blocks and oral pain medication 
to make the administration bearable. 
No adverse effects occurred, and the 
upper dose limit was not reached. The 
clear conclusion from the study was 
that a more patient-friendly method 
of delivery was needed. Richard 
Heller discussed the successful use 
of electroporation to facilitate deliv-
ery following intradermal injection of 
a plasmid encoding IL-12 to reduce 
or eliminate tumors in melanoma 
patients.
Thomas Schulze reported encour-
aging clinical results in a psoriasis 
study using decoy oligonucleotides 
(delivered by unguentum emulsi-
ficans) designed to bind and neutral-
ize transcription factors. Dan Yarosh 
described his experience with topi-
cally applied liposomes to deliver 
proteins (although they are not nucle-
ic acids, these proteins share many 
of the same delivery issues—both 
classes of macromolecule are high 
in molecular weight and are highly 
electrostatically charged), including 
a DNA repair enzyme (bacteriophage 
T4 endonuclease V). He presented 
promising clinical trial results in 
patients with xeroderma pigmento-
sum, actinic keratoses, and basal cell 
carcinomas.
emerging skin delivery technologies
Marianna Foldvari and Roger Kaspar 
presented work on topical formulations. 
Although the formulations present-
ed appear to penetrate the stratum 
corneum and deliver plasmid or 
siRNA to the epidermis (and der-
mis), there was some question as to 
whether functional nucleic acids were 
taken up by keratinocytes, because 
limited activity was observed. Kaspar 
reported results generated by Emilio 
Gonzalez at Stanford University, 
who demonstrated that the uptake of 
plasmid DNA and siRNAs by kerati-
nocytes following intradermal injec-
tions is probably the result of pressure 
(“pressure-fection”). Following intrad-
ermal injection of a fixed amount of 
plasmid DNA, enhanced expression of 
plasmid DNA correlated with increas-
ing vehicle volume. Paul Campbell 
described how ultrasound (sonopho-
resis) can generate targeted convec-
tion of microbubbles (microjetting) 
that enhance the delivery of nucleic 
acids. Marc Brown gave an overview 
of several topical formulations and 
physical transfer technologies with the 
potential to facilitate epidermal deliv-
ery. Samir Mitragotri described the use 
of needle-free liquid jets to generate 
high force and pressure to facilitate 
nucleic acid delivery.
The technique of microneedle 
arrays was well represented, with 
three presentations (by Tycho Speaker, 
Yeu-Cun Kim, and James Birchall) 
describing how projections of various 
types can penetrate the stratum cor-
neum to either deliver nucleic acids 
directly or generate breaches in the 
stratum corneum into which topical 
formulations can be applied. Finally, 
Daniel Gibson explained that ionto-
phoresis would help deliver fluores-
cently tagged oligonucleotides into 
the cornea and the skin of pigs.
Formulating a path to success
Dennis Roop gave a provocative presen-
tation on the future of skin therapeutics, 
including the potential therapeutic use 
of reprogrammed induced pluripotent 
stem (iPS) cells from patients (“individ-
ualized medicine”). He also described 
elegant proof-of-principle mouse siRNA 
experiments in which isolated keratino-
cyte stem cells were transduced with 
lentivirus expressing allele-specific 
siRNA, cultured, and reconstituted into 
skin equivalents that were subsequently 
grafted onto mice, which exhibited 
improved phenotype when compared 
with controls. He noted that, after lis-
tening to reports of the many delivery 
approaches at the meeting, he thought 
it likely that combinations of delivery 
technologies would be needed and that 
comparisons of delivery data generated 
within the community are essential.
During the culminating panel dis-
cussion (led by Christopher Contag, 
Peter Hull, and Irwin McLean), which 
focused on the best path forward for 
development of nucleic acid skin 
therapeutics with an emphasis on 
delivery technologies, a consensus 
emerged that the field would benefit 
from standardized animal models, 
skin-equivalent cell culture models, 
and organ culture models that use 
human skin. These validated skin 
models, along with common pools of 
reagents, would allow direct testing 
and evaluation of the various delivery 
strategies (i.e., allow comparison of 
“apples to apples”). The possibility of 
applying for American Reinvestment 
and Recovery Act stimulus funds—
National Institutes of Health (NIH) 
Grand Opportunities (GOs)—was 
proposed as a way to fund such proj-
ects. Following the meeting, a GO 
proposal was prepared and submitted 
to the NIH by US-based IPCC mem-
bers, with the aims of developing 
skin models (human and mouse) and 
sharing common reagents (expres-
sion plasmids, siRNA, and triplex 
oligonucleo tides) with researchers 
interested in testing and comparing 
delivery systems in well-characterized 
model systems. A complementary 
program grant application was made 
to the Medical Research Council by 
UK-based IPCC members to develop 
a range of animal models for validat-
ing and optimizing delivery of siRNA 
and other gene-silencing therapeutics 
into the skin and cornea.
Overall, there was enthusiasm 
through out the meeting regarding the 
future of siRNA and other nucleic acid 
therapies, with the realistic recognition 
that further development will re quire 
improved delivery technologies. A 
number of working groups were 
established to foster international com-
munication and collaboration and to 
continue the spirit of collegiality of the 
2009 meeting.
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